in fig1 , identical reference numerals denote identical or comparable components . fig1 shows an assembly according to the present disclosure . the assembly is surrounded by a housing 10 . the housing 10 comprises a right side member 12 , a left side member 14 , a distal bar 16 , a first bar 18 , a second bar 20 and a proximal bar 22 . all of these bars 16 , 18 , 20 , 22 comprise a central bore . a base frame 30 is arranged inside the housing 10 which comprises a bearing in which the base frame 30 is movable in axial direction with respect to the housing 10 . the base frame 30 comprises a right longitudinal bar 32 , a left longitudinal bar 34 , a front face 36 of the right longitudinal bar , a front face 38 of the left longitudinal bar , an actuator bar 40 , a support bar 42 and a proximal bar 44 of the base frame . the actuator bar 40 comprises a bore . a tube 64 is arranged inside this bore . a check valve is arranged inside the tube 64 . the tube 64 is connecting the reservoir container 70 and the dispensing container 60 . a needle unit 52 is adapted to the distal end 50 of the assembly . the needle unit 52 is seated over a second control member 54 . the second control member 54 is located in the flow path between an intermediate member 56 and the needle unit 52 . the first bar 18 of the housing 10 is located between the intermediate member 56 and the outlet 58 of the spherical body of the dispensing container 60 . the center of the first bar 18 comprises a bore to allow for a flow path between the dispensing container 60 and the needle unit 52 passing through the first bar 18 . at the proximal end 74 of the dispensing container 60 , an actuator bar 40 is located which comprises a small bore to define an aperture for a tube 64 which is connecting the dispensing container 60 with a reservoir container 70 . on the right and on the left side of the actuator bar 40 the front faces 36 , 38 of two longitudinal bars are shown . these front faces 36 , 38 are not flush with the surface of the actuator . a first control member 66 is arranged at a first outlet 68 located at the reservoir container 70 . the reservoir container 70 is surrounded and connected to a support bar 42 of the base frame 30 which is comprising a central opening . this ensures a secure connection of the reservoir container 70 to the housing 10 . at the proximal bar 44 of the base frame 44 , dose dispensing means 76 are shown which comprise a spring 72 . by pressing the dose dispensing means 76 , the base frame 30 is pushed towards the distal end 50 of the housing 10 . this movement causes a compression of the dispensing container 60 and liquid medicinal product is dispensed through the needle unit 52 . the distal movement is stopped by the abutment of the front faces 36 , 38 of the longitudinal bars of the base frame 30 with the first bar 18 of the housing 10 . the abutment indicates that the maximum dosage of the medicinal product is dispensed . this is the final position of the base frame during the dispensing process . due to the elastic behavior of the dispensing container 60 , the dispensing container 60 is withdrawing fluid medicinal product from the reservoir container 70 by suction . this process ends after the dispensing container 60 has reached its original shape . the check valve 54 ensures that just the fluid medicinal product from the reservoir container 70 is flowing into the dispensing container 60 by closing the dispensing flow path in proximal direction 74 . this is an effective method to prevent the intaking of air , tissue or blood into the dispensing container 60 . the spring 72 at the proximal end 74 of the assembly together with the elastic behavior of the dispensing container 60 after dispensing the fluid medicinal product enables the base frame 30 to be pushed back in proximal direction 74 . after the dispensing container 60 is refilled , the movement of the base frame 30 ends in its starting position . the term “ drug ” or “ medicament ”, as used herein , means a pharmaceutical formulation containing at least one pharmaceutically active compound , wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 da and / or is a peptide , a proteine , a polysaccharide , a vaccine , a dna , a rna , a antibody , an enzyme , an antibody , a hormone or an oligonucleotide , or a mixture of the above - mentioned pharmaceutically active compound , wherein in a further embodiment the pharmaceutically active compound is useful for the treatment and / or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy , thromboembolism disorders such as deep vein or pulmonary thromboembolism , acute coronary syndrome ( acs ), angina , myocardial infarction , cancer , macular degeneration , inflammation , hay fever , atherosclerosis and / or rheumatoid arthritis , wherein in a further embodiment the pharmaceutically active compound comprises at least one peptide for the treatment and / or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy , wherein in a further embodiment the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative , glucagon - like peptide ( glp - 1 ) or an analogue or derivative thereof , or exedin - 3 or exedin - 4 or an analogue or derivative of exedin - 3 or exedin - 4 . insulin analogues are for example gly ( a21 ), arg ( b31 ), arg ( b32 ) human insulin ; lys ( b3 ), glu ( b29 ) human insulin ; lys ( b28 ), pro ( b29 ) human insulin ; asp ( b28 ) human insulin ; human insulin , wherein proline in position b28 is replaced by asp , lys , leu , val or ala and wherein in position b29 lys may be replaced by pro ; ala ( b26 ) human insulin ; des ( b28 - b30 ) human insulin ; des ( b27 ) human insulin and des ( b30 ) human insulin . insulin derivates are for example b29 - n - myristoyl - des ( b30 ) human insulin ; b29 - n - palmitoyl - des ( b30 ) human insulin ; b29 - n - myristoyl human insulin ; b29 - n - palmitoyl human insulin ; b28 - n - myristoyl lysb28prob29 human insulin ; b28 - n - palmitoyl - lysb28prob29 human insulin ; b30 - n - myristoyl - thrb29lysb30 human insulin ; b30 - n - palmitoyl - thrb29lysb30 human insulin ; b29 - n —( n - palmitoyl - y - glutamyl )- des ( b30 ) human insulin ; b29 - n —( n - lithocholyl - y - glutamyl )- des ( b30 ) human insulin ; b29 - n -( ω - carboxyheptadecanoyl )- des ( b30 ) human insulin and b29 - n -( ω - carboxyheptadecanoyl ) human insulin . exendin - 4 for example means exendin - 4 ( 1 - 39 ), a peptide of the sequence h - his - gly - glu - gly - thr - phe - thr - ser - asp - leu - ser - lys - gln - met - glu - glu - glu - ala - val - arg - leu - phe - ile - glu - trp - leu - lys - asn - gly - gly - pro - ser - ser - gly - ala - pro - pro - pro - ser - nh2 . exendin - 4 derivatives are for example selected from the following list of compounds : h -( lys ) 4 - des pro36 , des pro37 exendin - 4 ( 1 - 39 )- nh2 , h -( lys ) 5 - des pro36 , des pro37 exendin - 4 ( 1 - 39 )- nh2 , des pro36 [ asp28 ] exendin - 4 ( 1 - 39 ), des pro36 [ isoasp28 ] exendin - 4 ( 1 - 39 ), des pro36 [ met ( o ) 14 , asp28 ] exendin - 4 ( 1 - 39 ), des pro36 [ met ( o ) 14 , isoasp28 ] exendin - 4 ( 1 - 39 ), des pro36 [ trp ( o2 ) 25 , asp28 ] exendin - 4 ( 1 - 39 ), des pro36 [ trp ( o2 ) 25 , isoasp28 ] exendin - 4 ( 1 - 39 ), des pro36 [ met ( o ) 14 trp ( o2 ) 25 , asp28 ] exendin - 4 ( 1 - 39 ), des pro36 [ met ( o ) 14 trp ( o2 ) 25 , isoasp28 ] exendin - 4 ( 1 - 39 ); or des pro36 [ asp28 ] exendin - 4 ( 1 - 39 ), des pro36 [ isoasp28 ] exendin - 4 ( 1 - 39 ), des pro36 [ met ( o ) 14 , asp28 ] exendin - 4 ( 1 - 39 ), des pro36 [ met ( o ) 14 , isoasp28 ] exendin - 4 ( 1 - 39 ), des pro36 [ trp ( o2 ) 25 , asp28 ] exendin - 4 ( 1 - 39 ), des pro36 [ trp ( o2 ) 25 , isoasp28 ] exendin - 4 ( 1 - 39 ), des pro36 [ met ( o ) 14 trp ( o2 ) 25 , asp28 ] exendin - 4 ( 1 - 39 ), des pro36 [ met ( o ) 14 trp ( o2 ) 25 , isoasp28 ] exendin - 4 ( 1 - 39 ), wherein the group - lys6 - nh2 may be bound to the c - terminus of the exendin - 4 derivative ; h -( lys ) 6 - des pro36 [ asp28 ] exendin - 4 ( 1 - 39 )- lys6 - nh2 , des asp28 pro36 , pro37 , pro38exendin - 4 ( 1 - 39 )- nh2 , h -( lys ) 6 - des pro36 , pro38 [ asp28 ] exendin - 4 ( 1 - 39 )- nh2 , h - asn -( glu ) 5des pro36 , pro37 , pro38 [ asp28 ] exendin - 4 ( 1 - 39 )- nh2 , des pro36 , pro37 , pro38 [ asp28 ] exendin - 4 ( 1 - 39 )-( lys ) 6 - nh2 , h -( lys ) 6 - des pro36 , pro37 , pro38 [ asp28 ] exendin - 4 ( 1 - 39 )-( lys ) 6 - nh2 , h - asn -( glu ) 5 - des pro36 , pro37 , pro38 [ asp28 ] exendin - 4 ( 1 - 39 )-( lys ) 6 - nh2 , h -( lys ) 6 - des pro36 [ trp ( o2 ) 25 , asp28 ] exendin - 4 ( 1 - 39 )- lys6 - nh2 , h - des asp28 pro36 , pro37 , pro38 [ trp ( o2 ) 25 ] exendin - 4 ( 1 - 39 )- nh2 , h -( lys ) 6 - des pro36 , pro37 , pro38 [ trp ( o2 ) 25 , asp28 ] exendin - 4 ( 1 - 39 )- nh2 , h - asn -( glu ) 5 - des pro36 , pro37 , pro38 [ trp ( o2 ) 25 , asp28 ] exendin - 4 ( 1 - 39 )- nh2 , des pro36 , pro37 , pro38 [ trp ( o2 ) 25 , asp28 ] exendin - 4 ( 1 - 39 )-( lys ) 6 - nh2 , h -( lys ) 6 - des pro36 , pro37 , pro38 [ trp ( o2 ) 25 , asp28 ] exendin - 4 ( 1 - 39 )-( lys ) 6 - nh2 , h - asn -( glu ) 5 - des pro36 , pro37 , pro38 [ trp ( o2 ) 25 , asp28 ] exendin - 4 ( 1 - 39 )-( lys ) 6 - nh2 , h -( lys ) 6 - des pro36 [ met ( o ) 14 , asp28 ] exendin - 4 ( 1 - 39 )- lys6 - nh2 , des met ( o ) 14 asp28 pro36 , pro37 , pro38 exendin - 4 ( 1 - 39 )- nh2 , h -( lys ) 6 - des pro36 , pro37 , pro38 [ met ( o ) 14 , asp28 ] exendin - 4 ( 1 - 39 )- nh2 , h - asn -( glu ) 5 - des pro36 , pro37 , pro38 [ met ( o ) 14 , asp28 ] exendin - 4 ( 1 - 39 )- nh2 , des pro36 , pro37 , pro38 [ met ( o ) 14 , asp28 ] exendin - 4 ( 1 - 39 )-( lys ) 6 - nh2 , h -( lys ) 6 - des pro36 , pro37 , pro38 [ met ( o ) 14 , asp28 ] exendin - 4 ( 1 - 39 )-( lys ) 6 - nh2 , h - asn -( glu ) 5 des pro36 , pro37 , pro38 [ met ( o ) 14 , asp28 ] exendin - 4 ( 1 - 39 )-( lys ) 6 - nh2 , h - lys6 - des pro36 [ met ( o ) 14 , trp ( o2 ) 25 , asp28 ] exendin - 4 ( 1 - 39 )- lys6 - nh2 , h - des asp28 pro36 , pro37 , pro38 [ met ( o ) 14 , trp ( o2 ) 25 ] exendin - 4 ( 1 - 39 )- nh2 , h -( lys ) 6 - des pro36 , pro37 , pro38 [ met ( o ) 14 , asp28 ] exendin - 4 ( 1 - 39 )- nh2 , h - asn -( glu ) 5 - des pro36 , pro37 , pro38 [ met ( o ) 14 , trp ( o2 ) 25 , asp28 ] exendin - 4 ( 1 - 39 )- nh2 , des pro36 , pro37 , pro38 [ met ( o ) 14 , trp ( o2 ) 25 , asp28 ] exendin - 4 ( 1 - 39 )-( lys ) 6 - nh2 , h -( lys ) 6 - des pro36 , pro37 , pro38 [ met ( o ) 14 , trp ( o2 ) 25 , asp28 ] exendin - 4 ( s1 - 39 )-( lys ) 6 - nh2 , h - asn -( glu ) 5 - des pro36 , pro37 , pro38 [ met ( o ) 14 , trp ( o2 ) 25 , asp28 ] exendin - 4 ( 1 - 39 )-( lys ) 6 - nh2 ; or a pharmaceutically acceptable salt or solvate of any one of the afore - mentioned exedin - 4 derivative . hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in rote liste , ed . 2008 , chapter 50 , such as gonadotropine ( follitropin , lutropin , choriongonadotropin , menotropin ), somatropine ( somatropin ), desmopressin , terlipressin , gonadorelin , triptorelin , leuprorelin , buserelin , nafarelin , goserelin . a polysaccharide is for example a glucosaminoglycane , a hyaluronic acid , a heparin , a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof , or a sulphated , e . g . a poly - sulphated form of the above - mentioned polysaccharides , and / or a pharmaceutically acceptable salt thereof . an example of a pharmaceutically acceptable salt of a poly - sulphated low molecular weight heparin is enoxaparin sodium . pharmaceutically acceptable salts are for example acid addition salts and basic salts . acid addition salts are e . g . hcl or hbr salts . basic salts are e . g . salts having a cation selected from alkali or alkaline , e . g . na +, or k +, or ca2 +, or an ammonium ion n +( r1 )( r2 )( r3 )( r4 ), wherein r1 to r4 independently of each other mean : hydrogen , an optionally substituted c1 - c6 - alkyl group , an optionally substituted c2 - c6 - alkenyl group , an optionally substituted c6 - c10 - aryl group , or an optionally substituted c6 - c10 - heteroaryl group . further examples of pharmaceutically acceptable salts are described in “ remington &# 39 ; s pharmaceutical sciences ” 17 . ed . alfonso r . gennaro ( ed . ), mark publishing company , easton , pa ., u . s . a ., 1985 and in encyclopedia of pharmaceutical technology .
the present invention relates to an assembly for a drug delivery device comprising a dispensing container and a reservoir container for holding a fluid medicinal product , wherein the dispensing container and the reservoir container are connected to one another and are in fluid communication , and wherein the dispensing container is squeezable for dispensing a dose of the fluid medicinal product from the dispensing container , the dispensing container being refillable with the fluid medicinal product from the reservoir container .